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Abstract
Background: Upper limb orthoses are frequently prescribed for children with cerebral palsy (CP) who have muscle
overactivity predominantly due to spasticity, with little evidence of long-term effectiveness. Clinical consensus is
that orthoses help to preserve range of movement: nevertheless, they can be complex to construct, expensive,
uncomfortable and require commitment from parents and children to wear. This protocol paper describes a
randomised controlled trial to evaluate whether long-term use of rigid wrist/hand orthoses (WHO) in children with
CP, combined with usual multidisciplinary care, can prevent or reduce musculoskeletal impairments, including
muscle stiffness/tone and loss of movement range, compared to usual multidisciplinary care alone.
Methods/design: This pragmatic, multicentre, assessor-blinded randomised controlled trial with economic analysis
will recruit 194 children with CP, aged 5–15 years, who present with flexor muscle stiffness of the wrist and/or
fingers/thumb (Modified Ashworth Scale score ≥1). Children, recruited from treatment centres in Victoria, New
South Wales and Western Australia, will be randomised to groups (1:1 allocation) using concealed procedures. All
children will receive care typically provided by their treating organisation. The treatment group will receive a
custom-made serially adjustable rigid WHO, prescribed for 6 h nightly (or daily) to wear for 3 years. An application
developed for mobile devices will monitor WHO wearing time and adverse events. The control group will not
receive a WHO, and will cease wearing one if previously prescribed. Outcomes will be measured 6 monthly
over a period of 3 years. The primary outcome is passive range of wrist extension, measured with fingers
extended using a goniometer at 3 years. Secondary outcomes include muscle stiffness, spasticity, pain, grip
strength and hand deformity. Activity, participation, quality of life, cost and cost-effectiveness will also be
assessed.
Discussion: This study will provide evidence to inform clinicians, services, funding agencies and parents/carers
of children with CP whether the provision of a rigid WHO to reduce upper limb impairment, in combination
with usual multidisciplinary care, is worth the effort and costs.
Trial registration: ANZ Clinical Trials Registry: U1111-1164-0572.
Keywords: Upper extremity, Splint, Orthosis, Children, Cerebral palsy, Occupational therapy, Intervention,
Randomised trial, Cost-effectiveness
* Correspondence: Christine.imms@acu.edu.au
1Centre for Disability and Development Research, Faculty of Health Sciences,
Australian Catholic University, 17 Young Street, Fitzroy, VIC 3065, Australia
Full list of author information is available at the end of the article
© 2016 Imms et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Imms et al. BMC Pediatrics  (2016) 16:70 
DOI 10.1186/s12887-016-0608-8
Background
Cerebral palsy (CP), the most common physical disability
in childhood, is a group of disorders of the development
of movement and posture that occur as a result of distur-
bances in the foetal or infant brain [1]. The motor impair-
ment may be accompanied by co-morbidities, including
epilepsy, vision or hearing loss, intellectual disability, dis-
orders of communication, behavioural difficulties, and sec-
ondary musculoskeletal problems [1]. The most common
motor disorder in CP is spasticity, occurring in 86 % of in-
dividuals [2]. Spasticity is a velocity-dependent increase in
the tonic stretch reflex, with exaggerated tendon reflexes
[3] and is characterised by slow, effortful movement [4].
This research is embedded within an International
Classification of Functioning, Disability and Health (ICF)
framework [5] that articulates a dynamic interaction be-
tween impairments at body structure and function level,
activity performance and participation. At the body
function level, muscle over-activity as result of spasticity
and/or dystonia plays a significant role in the development
of secondary musculoskeletal impairments in the upper
limbs [6] that are common in CP. Secondary impairments
include muscle stiffness, loss of active range of movement,
joint contracture and pain. Diminished skeletal muscle
growth is a key feature in the aetiology of contracture and
deformity [6]. Persistent over-activity of skeletal muscle,
and subsequent maintenance of a shortened position, can
cause a failure of longitudinal muscle growth and muscle
adaptation, including increased resistance to passive stretch
or stiffness [6, 7]. Subsequently there is a biomechanical
imbalance of bone to muscle, as bone continues to grow
and muscle growth is impeded [7]. The combined im-
pact of these factors can result in soft tissue retraction,
loss of active and passive range of motion and joint
contracture [6, 8].
Progressive changes in muscle length and stiffening of
joints in the upper limbs can ultimately result in a lim-
ited ability to reach, grasp and manipulate objects or, in
some individuals, a complete lack of functional use of
the hands. Strong correlations exist between the degree
of upper limb deformity and activity performance [9].
When combined with neurological dysfunction, upper-
limb musculoskeletal impairments significantly impact
on the ability of children to use their hands to perform
daily activities, attain age appropriate independence and
develop the autonomy and skills required to participate
in activities of importance in home, school and commu-
nity environments [10, 11].
Children with CP are not born with musculoskeletal
impairments. There is evidence however, that in children
with spastic motor types, these impairments begin to
manifest prior to three years of age [12] and that increas-
ing stiffness and progressive loss of range of movement
occurs throughout childhood and adolescence [13–15].
A range of treatment options are available for children
with CP that specifically focus on improving hand use.
These include activity-based interventions such as goal-
directed training, intensive bimanual therapy, modified
constraint-induced movement therapy and home pro-
grams. Each of these interventions aim to achieve child/
parent-focused goals, and has high-level evidence sup-
porting their effectiveness for increasing activity-level
performance and goal achievement [16]. Little evidence
is available however, about whether activity-level inter-
ventions improve range of movement and reduce sec-
ondary musculoskeletal impairments. In addition to
activity-based therapies, injection of Botulinum toxin A
(BoNT-A) into overactive muscle groups is known to
reduce muscle overactivity and has been associated with
improved range of movement during a period of chemical
denervation, therefore enhancing the effects of upper ex-
tremity therapy and the potential for goal achievement and
activity performance [17]. Nevertheless, BoNT-A alone in
the upper limbs has been shown to have little sustained ef-
fect on range of movement [17]. Upper limb surgery is also
available to correct deformity once present, although out-
comes are variable [18].
Removable orthoses (also called splints) are applied to
the forearms, wrists and hands with the goal of either
maintaining muscle length and joint range of movement
through sustained stretch, or enhancing functional per-
formance. Although orthoses are commonly integrated
into intervention strategies with children with CP, there
is little evidence supporting the use of upper limb orthoses
and wide variation in their prescription, manufacture and
intended aims [10, 19]. One controlled trial [20] demon-
strated improved effect of BoNT-A when combined with
static splinting (term used in the trial by Kanellopoulos et
al.) in children with CP. A Cochrane systematic review by
Katalinic et al. [21], which included adults and children
with a broad range of neurological and non-neurological
conditions, demonstrated little benefit of stretching for
preventing or reducing contractures. The review con-
cluded that the use of interventions that provided a stretch
to muscles, such as upper limb orthoses, be ceased [21].
The application of these findings to children with CP how-
ever, is limited. Only five of the 35 randomised trials in-
cluded children. Of these, three studies included children
with CP and each of these evaluated the effects of casting
(one in the upper and two in the lower limb) as opposed
to orthosis wear. A more recent systematic review of the
effectiveness of upper limb orthoses for children with CP
found more equivocal evidence than Katalinic et al. and
recommended further methodologically strong research
be completed to more effectively inform practice [22].
The clinical rationale for providing upper extremity
orthoses is multi-faceted, with both short and long term
goals. The focus of the current study is on rigid wrist/
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hand orthoses (WHO). The primary goal of wearing
rigid WHO for all children with CP is to prevent the de-
velopment of muscle stiffness, maintain the integrity of
soft tissues and prevent the development of abnormal
postures and long-term deformity. Due to the diverse
nature of CP, the secondary goals generally depend on
the child’s Manual Ability Classification System (MACS)
level. The MACS is a five-level system that describes
how children use their hands to handle objects during
daily activities [23]. For children in MACS levels I to III,
who are able to handle objects in daily life, the second-
ary aims of WHO prescription are to improve or main-
tain activity performance and participation through
maintenance of good posture for functional use of the
hand. Children in MACS levels IV and V have little or
no functional use of the upper limb(s) and the aim of
wearing of a rigid WHO is to maintain posture to fa-
cilitate ease of care-giving during daily activities such
as bathing, dressing and positioning. Wearing of a rigid
WHO is also used to prevent complications associated
with muscle shortening such as pain and poor palmar
skin hygiene.
Application of the results of previous research has
been limited by the length of time in which WHO have
been applied and evaluated (often <6 months). These time
frames are often dictated by the cost of implementing a
trial. However, orthosis wear is an intervention aiming for
long-term benefits (i.e. the reduction of contracture over
time), thus clinicians are appropriately reluctant to change
practice based on short-term research evidence. A well-
designed large trial with a long intervention and follow-up
period is now critical to determine the long-term outcome
of this intervention. This 3 year trial has been designed to
balance the need for longitudinal evidence with the com-
plexities of attaining prolonged adherence of participants
to an intervention within a controlled trial.
Effective and feasible rigid WHO are those where the
benefits outweigh the risks associated with the intervention
such as client discomfort, potential for skin breakdown,
carer burden in maintaining routine application, follow-up
appointments for manufacture and adjustment. Provision
of WHO should also contribute positively to the long-term
goals of children and families in terms of achievement of
participation in meaningful activities during childhood and/
or improved ease of caring for children with CP. Cost-
effective rigid WHO are those where the benefits outweigh
the net costs (defined as cost of the intervention minus the
cost offsets) and/or where the relationship between the net
costs and outcomes is deemed acceptable (i.e. less than a
common decision threshold in Australia, such as <$50,000
per Quality Adjusted Life Year (QALY)). Affordable rigid
WHO are those where the financial costs for materials,
construction and monitoring are within the available
budget of third party funders and/or parents.
Wrist-hand orthoses interventions, in combination with
activity-based therapy, are aimed at maintaining muscle
length, strength and balance, which are required for
optimum force generation, effective grasp and manipula-
tion [24] and therefore functional use of affected hands in
daily activities. The primary aim of this research is, there-
fore, to evaluate whether use of rigid WHO over 3 years
in children with CP, combined with usual multidisciplinary
care, can prevent or reduce musculoskeletal impairment
including loss of range of movement and muscle stiffness
at the wrist, compared to usual multidisciplinary care
alone. The impact of WHO wear on pain, activity per-
formance and participation, as well as ease of caregiving
for families will be evaluated along with an assessment of
cost-effectiveness of the intervention.
Research questions
In children aged 5 to 15 years with CP, does the provision
of a serially adjustable rigid WHO in combination with
usual multidisciplinary care, compared to usual multidis-
ciplinary care alone:
1. Reduce body function and structure impairment
including contracture, defined as fixed loss of range
of movement, or prevent further loss of range of
movement at the wrist, and reduce pain and muscle
stiffness at three years from the beginning of the
study? This is the primary research question.
2. Improve activity performance and/or ease of caregiving
at three years from the beginning of the study?
3. Influence participation and quality of life at three
years from the beginning of the study?
In children aged ≥5 years with CP:
4. What are the effects of the interaction between age
and provision of the WHO plus usual care, and the
interaction between severity and provision of the
WHO plus usual care, compared to usual care alone,
in reducing or preventing further loss of range of
movement, muscle stiffness or pain, or improving
activity performance or ease of caregiving, at three
years from the beginning of the study?
5. What are the incremental costs and potential cost
offsets of adding a rigid WHO to usual care
compared with usual care alone?
6. From a health sector perspective, what is the cost-
effectiveness of providing a rigid WHO combined
with usual care, compared to usual care alone?
Trial registration
This study has been registered with the Australian and
New Zealand Clinical Trials Registry: U1111-1164-0572.
Table 1 displays key registration data.
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Methods
Design
This study is a pragmatic, prospective, multicentre,
assessor-blinded randomised controlled trial (RCT) with
economic analysis that aims to measure the effectiveness
of the intervention under usual multidisciplinary care
conditions [25]. It will incorporate a two-arm, parallel
group superiority design and 1:1 allocation of children
to wear WHO and participate in usual multi-disciplinary
care or to multidisciplinary care alone. Assessments
Table 1 Minimising impairment trial registration data: Protocol Version 3: 30.10.2014
Data Category Information
Primary registry and trial identification number ANZ Clinical Trials Register: U1111-1164-0572
Date of registration in primary registry 5.12.2014
Secondary identification numbers N/A
Sources of money or material support Australian Catholic University; National Health and Medical Research Council, Australia
Primary Sponsor Investigator led: Professor Christine Imms
Contact for public queries Dr Melinda Randall: Melinda.randall@acu.edu.au
Contact for scientific queries Prof Christine Imms: Christine.imms@acu.edu.au
Public title Minimising impairment: a multicentre randomised controlled trial of upper limb orthoses
for children with cerebral palsy.
Scientific title Does wearing a rigid upper limb wrist hand orthosis in combination with evidence informed
occupational therapy, compared to evidence informed occupational therapy alone, reduce wrist/
hand impairment and improve activity and participation outcomes in children aged 5–15 years
with cerebral palsy?
Countries of recruitment Australia
Health condition studied Cerebral palsy
Intervention Intervention: custom-made serially adjustable rigid wrist hand orthoses to maintain the flexor
compartment (muscles of the wrist, fingers and thumb) in a lengthened position to avoid
shortening of the musculo-tendinous unit and other soft tissue.
Control: The control group will not receive a rigid wrist/hand orthosis.
Both groups: will receive care typically provided by their usual treating organisation. Possible
treatments may include developmentally appropriate, goal focused and evidence-informed
occupational therapy, the use of equipment or BoNT-A injections.
Key inclusion/exclusion criteria Ages eligible for study: 5–15 years; Gender eligible: both;
Inclusion criteria: A confirmed diagnosis of cerebral palsy as recorded in the medical history;
Presence of flexor muscle stiffness - score at least 1 on the Modified Ashworth Scale during wrist
extension with fingers extended; May or may not already exhibit contracture at the wrist.
Exclusion criteria: upper limb dystonia without the presence of spasticity; an allergy or sensitivity to
the materials used to construct orthoses; if families are unable to access the study site at the
necessary times; and if families identify factors (e.g. child’s behaviour) that impact significantly on
their ability to carry out the intervention
Study type Interventional
Allocation: randomised; intervention model: parallel assignment; Masking: Single blind.
Primary purpose:
Date of first enrolment 28.8.2015
Target sample size 194
Recruitment status Recruiting
Primary outcomes Passive range of wrist extension (measured with the fingers extended) measured using a
goniometer at 3 years; Active range of wrist movement measured using standardised goniometric
measurement and use of clinometer for measures of supination and inertial motion sensors
measures at 3 years;
Key secondary outcomes Body function outcomes: Muscle tone; muscle spasticity; grip strength; hand deformity and pain.
Activity outcomes: Self-care; Manual ability; Hand speed and dexterity; ease of care.
Participation outcomes: Attendance and involvement in home, school and community activities.
Quality of Life outcomes: Child and parent.
Health economics outcomes: relative cost and cost-effectiveness.
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will be completed at baseline, and every 6 months for
3 years.
Participants
Child participants
Eligible children will be aged 5 to 15 years at the time of
recruitment; diagnosed with CP as recorded in their
medical history; and present with flexor muscle stiffness
of the wrist as indicated by a Modified Ashworth Scale
score ≥1 during wrist extension with fingers extended.
Children may or may not already exhibit contracture.
Parents are required to be able to understand written
and spoken English as it is not feasible to translate all
study materials into languages other than English.
Prior upper limb surgery is not an exclusion criteria,
however, to avoid interfering with surgical outcomes
children will only be eligible if they are at least 12 months
post-surgery. In addition, children will be excluded from
this study if they have upper limb dystonia without the
presence of spasticity; an allergy or sensitivity to the mate-
rials used to construct orthoses; if families are unable to
access the study site at the necessary times; and if families
identify factors (e.g. child’s behaviour) that impact signifi-
cantly on their ability to carry out the intervention.
Therapist participants
Therapists providing the WHO for any child recruited
to the study may be occupational therapists or physio-
therapists. They will be asked to consent to providing
data related to their discipline and experience, and about
the design and fabrication of orthoses they provide to re-
cruited child-participants at each occasion of manufacture
or adjustment.
Ethics
Ethical approval has been received from the Australian
Catholic University (HREC: 2014 317 V), Cerebral Palsy
Alliance in NSW (HREC: 214-08-02), Monash Children’s
Hospital (HREC: 14199B) and The Royal Children’s Hos-
pital (HREC: 34280A) in Victoria and the Princess Mar-
garet Hospital in Western Australia (HREC: 2014060).
Parents or guardians of all child-participants will provide
informed written consent for their child to take part in
the study, as well as consent to complete questionnaires.
Children aged 12 years or older will be asked to assent
to taking part in the trial if they are capable of doing so.
Modifications to the protocol will be reported to each
HREC, all investigators and noted on the trial registry.
Sample size
Sample size calculations were performed according to the
primary dependent variable: passive range of movement of
wrist extension (measured with fingers extended) at 3 years.
Sample size calculations were based on data provided by
Rameckers et al. [26] who reported a baseline standard de-
viation (SD) of 12.4° of passive wrist extension in a group
with hemiplegic CP. Rameckers et al. [26] included a more
homogeneous group of children than we intend and,
therefore, in the absence of clear evidence in the literature,
the variability has been estimated to approximate 22° (10°
greater than Rameckers et al.’s more homogenous group).
Based on a SD of 22° for the primary outcome, 77 par-
ticipants per group would be required to detect a 10°
between-group difference in passive range of movement at
36 months with 80 % power and a two-tailed level of sig-
nificance of 0.05. A 10° difference was chosen as differences
greater than 5 to 10° of movement are deemed clinically
important [21]. We used data from our previous success-
fully completed RCTs of upper limb interventions for chil-
dren with CP to estimate withdrawal and loss-to-follow-up
rates. Prior withdrawal rates ranged from 0 to 10 %, with
an additional loss-to-follow up in these RCTs ranging from
0 to 3 % over periods of 6 months. We anticipate that loss-
to-follow up in this 3 year study will be higher than 3 %,
and thus estimate a 10 % loss. Consequently we predict a
combined withdrawal/loss-to-follow-up rate of 20 %. Based
on these estimates, we aim to recruit 194 children. Of note,
children may have both limbs included in the study. The
presence of two limbs was not included in the sample
estimates but will be used in the analyses. Including
both limbs will increase study power; hence the sample
size is expected to be conservative if two limbs are in-
cluded for some children. Randomised trial experience
in Australia suggests we will require at least 12 months
to recruit the required sample.
Recruitment
This multicentre trial will be conducted in Victoria
(Monash Children’s Hospital and The Royal Children’s
Hospital), Western Australia (Princess Margaret Hospital
and The Ability Centre) and New South Wales (Cerebral
Palsy Alliance). The treating clinical teams at each trial
site will identify potential participants and provide written
and verbal information about the study to potential fam-
ilies (see Fig. 1: Study flowchart). Study advertisements,
which will include contact details for the project coordin-
ator and the research assistant assigned to respective sites,
will be distributed to clinicians and families. Further
advertising will be done through site-specific newsletters,
websites and social media with an invitation to contact
study personnel or treating therapists for more informa-
tion about the study. Eligibility will be determined through
discussion with parents and clinical examination of the
child’s upper limb/s.
Randomisation
Once consent and assent (for those children aged 12 years
or more) has been obtained by the research assistant, and
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following baseline assessment, children will be randomised
to either the treatment or comparison group with an al-
location ratio of 1:1, using a web-based randomisation
procedure to ensure concealed allocation. Randomisa-
tion will be completed using randomly permuted blocks
of variable length, stratified by study centre (5 strata),
and by passive wrist range of movement (3 strata: wrist
extension >0° (fingers extended); wrist extension be-
tween −45°-0° (fingers extended); or wrist extension < -45°
(with or without finger extension)). For children with bilat-
eral involvement, where both limbs meet inclusion criteria,
both limbs will be allocated to the same intervention based
on the randomisation sequence and stratification will be
based on the passive wrist range of the more involved limb.
Data will be collected for both upper limbs and included
in the analysis at the end of the study for limb-based
outcomes.
Interventions
All children will receive care typically provided by their
usual treating organisation. Possible treatments include
occupational therapy (e.g. goal-directed training, intensive
bimanual therapy), prescription and use of equipment
and /or BoNT-A injections. Some children may already
have been prescribed a WHO. The WHO of those chil-
dren allocated to the intervention group will be assessed
Fig. 1 Study flow diagram. ICF: International Classification of Functioning, Disability and Health; BS&F: body structure and function
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to ensure it meets the intervention protocol, and adjusted
if necessary. Those in the control will cease wearing their
WHO. Due to the pragmatic nature of this trial, study
duration and anticipated heterogeneity of the study
sample and possible co-interventions, it will not be pos-
sible to standardise co-interventions, however a detailed
log will be kept and efficacy/efficiency implications of a
non-standardised comparator will be carefully assessed.
Treatment group
The treatment group will receive a custom-made serially
adjustable rigid WHO to maintain the flexor compart-
ment (muscles of the wrist, fingers and thumb) in a
lengthened position to avoid shortening of the musculo-
tendinous unit and other soft tissue. For children with
unilateral involvement only one hand will be provided
with an orthosis. For children with bilateral involvement,
both hands will be treated if clinically indicated. The
WHO may involve variations of a volar or dorsal/volar
orthosis. Volar orthoses are placed on the palmar aspect
of the hand and forearm; dorsal/volar orthoses have a
component on the palm and a second, linked compo-
nent on the back of the forearm. Both types of orthoses
are designed and fabricated to achieve the same aims.
Orthoses will be made of thermoplastic material, which
when gently heated loses rigidity allowing it to be con-
formed to the child’s arm in the required position. On
cooling, thermoplastics regain rigidity. Straps will be used
to maintain the correct position of the child’s wrist/hand
in the orthosis.
As there is no evidence to guide the optimal position
to achieve with orthoses, wearing regimes or follow-up
procedures, a national group of expert occupational
therapists developed consensus-based guidelines to in-
clude in the study operating procedures. Rather than
specify muscle and joint positions to achieve with orth-
oses, these guidelines provide principles to guide indivi-
dualised positioning of the thumb, fingers and wrist in the
orthosis based on the available passive range of motion of
the flexor compartment and the relative contribution of
wrist and finger flexor stiffness. Briefly, the thumb is posi-
tioned midway between full extension and abduction to
maintain web space while avoiding metacarpal-phalangeal
(MCP) joint hyperextension. Fingers are placed in a small
amount of flexion (10–30° at MCP and inter-phalangeal
joints) to prevent the hand slipping in the orthosis. The
orthosis is then fabricated to maintain thumb and finger
position with the wrist positioned in the orthosis to
achieve stretch to the flexor compartment. Each WHO
will be fabricated following a clinical assessment of the
child’s range of motion and muscle tone. Therapists in
participating study sites will fabricate the orthoses as
part of their usual clinical duties to achieve an indivi-
dualised position of the wrist and hand according to
pre-determined principles outlined in the consensus-
based guidelines.
To achieve a prolonged positioning effect, children will
be asked to wear the orthosis for a minimum of 6 h for
each 24 h period of the 3 years of the study [27]. Al-
though night time wear is recommended, it may be ap-
propriate for some children to wear the orthosis during
the day: for instance, children with more severe impair-
ments who do not use their hands to carry out activities
and therefore for whom wearing a WHO is unlikely to
impact on functional hand use. Children with bilateral
upper limb involvement where both hands meet the cri-
teria for wearing an orthosis will be asked to wear both
orthoses each night. If sleep quality is compromised as a
result of concurrently worn bilateral orthoses, recommen-
dations will be to: (i) wear both orthoses each day; or (ii)
wear one orthosis at night, the other during the day; or
(iii) alternate wear of each orthosis on alternating nights.
The therapists who manufacture the WHO will monitor
them in a manner consistent with usual clinical practice.
Orthoses will be replaced or serially adjusted over time ac-
cording to clinical indications to accommodate growth,
ensure good fit and maintain appropriate positioning.
Serial adjustment involves re-heating the orthosis and
remoulding it to achieve an adjusted position. The al-
tered position may be in a position of greater wrist/fin-
ger extension in response to improvement in range of
motion or reduced muscle stiffness, or in a position of
reduced wrist/finger position if range of motion de-
creases or muscle stiffness increases.
Families will be provided with verbal and written in-
structions for donning, caring for and cleaning the orth-
oses; wearing regimes and guidance for facilitating the
child to wear orthoses. Consistent with usual clinical prac-
tice, families will be asked to contact the therapist who
manufactured the WHO if any difficulties with orthosis
wear arise such as rash, red marks, bruises, pain or diffi-
culties wearing the orthosis for 6 h per 24 h period.
Fidelity of intervention will be considered in three
ways. Therapists fabricating orthoses will be educated by
study personnel regarding study requirements, orthoses
fabrication and wearing principles, which will also be
documented in the standard operating procedures pro-
vided to each participating therapist. Participating thera-
pists will complete a questionnaire to record details of
the design and fabrication of the orthosis and photo-
graph each orthosis on completion of fabrication to pro-
vide study personnel with a digital image for evaluating
orthosis manufacture against the pre-determined princi-
ples. These photographs will also enable assessment of
the nature and design of orthoses used in the study.
Data related to adjustments made to the WHO over the
study period will also be collected. Finally, the frequency
and duration that each child wears the orthosis will be
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recorded daily using a custom-designed application for
Android and Apple mobile devices known as Therapy
App (TherApp) (see Intervention adherence for details).
Control group
The control group will receive usual multidisciplinary care
without a WHO. Prior to consenting, parents will under-
stand that a child entering the study with a prescribed
WHO and allocated to the control group will cease wear-
ing it. Parents and children will be advised there is debate
about effectiveness; the study will generate evidence to
inform future practice. They will also be informed that
children in either group could lose ROM during the
trial period as this is the natural history of CP, and because
of this, their child will be monitored closely throughout
the 3 year study period.
Intervention – modifications
Children in either group could lose range of movement
through the trial period as this is the natural history of
CP. In addition, the trial will run for an extended period
(3 years) during which growth and physical development
will influence children’s outcomes. Both groups will,
therefore, be carefully monitored for loss of range of
motion over time.
Children will be monitored for the first 12 months fol-
lowing enrolment according to the study protocol and will
not receive any modification to the intervention during
this period. Children assessed at or after the 12-month
time point who have lost ≥30° passive range of wrist ex-
tension or increased by ≥2 categories on the Modified
Ashworth Scale, compared to baseline, in either group will
be eligible for increased monitoring. This involves re-
assessment at 3-monthly intervals and may, in consult-
ation with the child’s parents and treating team, involve
either serial casting to regain range of movement and/or a
referral for a surgical opinion. Casting is common clinical
practice in children with CP to achieve increased passive
range of motion over the short term [10].
Criteria for withdrawal
Withdrawal criteria, which apply to all children, have
been specified a-priori to ensure child safety, quality of
study data, and the ability to answer the research ques-
tions. Children who receive a diagnosis other than CP or
their movement disorder evolves to dystonia without the
presence of spasticity, will be withdrawn from the study
and all data removed from analyses. Children who have
a surgical intervention to the included upper limb or
more than three episodes of casting as a modification to
treatment during the course of the study may discon-
tinue study treatment but will be followed until study
completion and be included in the statistical analyses
where possible.
Concomitant care
Children may participate in a range of upper limb interven-
tions throughout the study according to usual multidiscip-
linary care, such as assistive technology or equipment and
devices, upper limb BoNT-A injections, intensive bimanual
therapy, early intervention, goal-directed training, home
programs, modified constraint-induced movement therapy,
or parent education/coaching [16]. Choice of concomitant
interventions will be determined by the child’s family and
treating team and will be recorded.
Intervention adherence
Adherence to the allocated intervention will be recorded
using TherApp, which is the equivalent to an electronic
diary. TherApp will be used in conjunction with a study-
specific questionnaire to assist with measurement of
WHO adherence, type of co-interventions and incidence
of side effects from orthosis wear. Families of children
with CP were consulted about the content, feasibility and
implementation of TherApp.
Group allocation (concealed from the assessors) and
personal details will be programmed into TherApp at the
time of randomisation to ensure appropriate questions are
asked about each child. Parents nominate the time for a
daily and/or weekly reminder to be sent to their phone or
device. For children in the intervention group, TherApp
sends a daily prompt to parents requesting information on
daily wearing duration and a weekly request for details on
adverse events due to wearing orthoses, or any difficulties
the child or family experience with wearing orthoses.
TherApp will prompt parents to contact their child’s treat-
ing therapist if needed. We anticipate this will facilitate ad-
herence to the provision of the WHO and contribute to
treatment fidelity. If TherApp registers no response to the
daily prompt, an automated email alert to the research as-
sistant enables appropriate follow up. Parents of children
in both groups will also receive a weekly TherApp request
to record upper limb therapy received in the previous
week. Data recorded on TherApp will be extracted
prior to each assessment period and supplemented with
6-monthly parent interviews to record additional details
about concomitant therapy in the preceding period.
In addition to the TherApp, a novel pressure sensor
has been engineered to record the time orthoses are
worn. Three sensors will be implanted in the contact-
surface of the orthosis (under the thumb, fingers and
wrist). The sensors developed for this study use wireless,
blue tooth technology and have a sampling rate of 1Hz
per second. This tiny device is printed on material safe
for human consumption using 3-Dimensional printing
technology to meet the combined requirements of ac-
curate measurement, protection of skin integrity associ-
ated with device pressure and protection of the child
from swallowing a small item. Data obtained from the
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sensor will be used to validate parent-report data ex-
tracted from the TherApp in a subset of participants.
Data collection and analyses
Assessors and details of blinding
Assessors will be occupational therapists or physiothera-
pists blinded to the treatment group of the child. Each
assessor will be trained by a chief investigator in reliable
administration of all measures and provided with a study
assessment protocol to ensure consistency of assessment
techniques between assessors. Multiple efforts will be
made to retain blinded status of assessors. Treating ther-
apists, research personnel, child-participants and families
will be routinely reminded that it is critical that blinding
of the assessor is retained and the assessor will remind
the family of this on initial contact at each assessment.
Study numbers allocated to children will not contain a
fixed code denoting intervention group. The success of
blinding will not be measured as methodological experts
argue against such practice [28]. Therapists providing
the WHO are unable to be blinded to treatment group
and hence may adjust co-interventions differently in the
two groups. Measurement of co-interventions and com-
parisons between groups is therefore is an important
part of this trial. Blinding of parents and participants to
intervention group is not possible.
Demographic and diagnostic characteristics
Consistent with best practice in CP [1], the severity of
CP will be assessed and classified at baseline using the
Gross Motor Function Classification System [29], Manual
Ability Classification System [23], Communication Func-
tion Classification System [30] and Bimanual Fine Motor
Function scale [31]. In addition, the type of movement dis-
order (that is, spastic or mixed) and severity of spasticity
in the included upper limb(s) will be rated using the
Hypertonia Assessment Tool [32] and the Australian
Spasticity Assessment Scale [33, 34] respectively. Informa-
tion from these tools will help to describe the characteris-
tics of the study sample and be used in post-hoc analyses
of outcomes. A study specific questionnaire will measure a
range of demographic and other variables including age,
gender, associated conditions (intellectual disability, sen-
sory impairments), family configuration, range of services
received and socio-economic status as defined using the
Socio-Economic Index for Areas data [35].
Outcome measures
The primary outcome measure is passive range of wrist
extension (measured with the fingers extended). Range
of wrist movement is operationalised from -70° (full
wrist flexion) to + 80° (full wrist extension) where 0° indi-
cates a neutral position. Range of movement will be mea-
sured using a goniometer for extension/flexion movements,
an inclinometer for supination/pronation and inertial mo-
tion sensors. Inertial motion sensors, constructed specific-
ally for the trial, will be used to measure active and passive
wrist extension, with fingers extended as well as functional
range of wrist extension elicited during standardised tasks.
Other measures across the domains of the ICF will also be
used to evaluate the effect of the intervention. Table 2
displays each variable, the measurement tool selected
and provides an overview of psychometric evidence for
the selected tools.
Economic analysis
Economic analysis in the context of trials is designed to
answer one or both of two questions: i) does the treatment
being evaluated offer value-for-money (i.e. ‘allocative effi-
ciency’); and ii) if so, how best to design/implement it (i.e.
‘technical efficiency’). In this trial we are focussed on tech-
nical efficiency. Specifically, is the care pathway more
cost-effective with the addition of a WHO for children
with CP than without? Economic methods have been
chosen therefore to focus on appraisal using trial-based
data (with limited economic modelling) and to deal with
variability in usual multidisciplinary care. A comprehensive
analysis of usual care activities will enable: i) specification of
a weighted average usual care pathway (i.e. weighted by ac-
tivity prevalence); ii) incremental cost-effectiveness ratios
(ICERs) presented by state/site, as well as by overall trial
results; and iii) extensive sensitivity/uncertainty analyses
to detail cost and outcome drivers.
The technical efficiency focus will make cost-effectiveness
analysis (CEA) and cost consequences analysis (CCA)
the primary analysis, with ICERs that focus on body
function, activity measures and child/family quality of
life and health utility outcomes from both health sector
and service funder perspectives. The key trial-based
ICERs are: i) the ‘net cost per 10° improvement in pas-
sive range of movement at 3 years’; ii) the ‘net cost per
unit of improvement on the Cerebral Palsy-Quality of
Life’ measure; iii) the ‘net cost per Adult Quality of
Life-8 Dimensions’ [36] improvement for parent/carer;
and iv) the ‘net cost per Child Health Utility 9D’ [37]
improvements for children. While economic quality of
life instruments are usually focussed on value-for-money
comparisons, the difficulties in modelling longer term out-
comes in this trial, leads to their primary purpose being to
help establish technical efficiency. ICERs will be reported
as both point and range estimates. In the CCA, ICERs will
be reported and interpreted alongside the full range of
body function and activity measures collected. A Cost-
Utility Analysis (CUA) with variable time horizons and
best available data will be included in sensitivity analysis
against a specified decision threshold (i.e. < $50,000 per
QALY). In addition to the CEA/CCA and CUA, a broader
economic approach will be undertaken to capture policy
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Table 2 Variables and outcome measures
Variable Measurement tool Additional information
ICF level: Body function: baseline, 6, 12, 18, 24, 30, 36 months
Passive range of motion: elbow extension,
wrist extension (with fingers extended), wrist
extension (with fingers flexed), supination
Standardised goniometric measurement;
inclinometer for measures of supination;
Goniometric measurements have a high level of
intra-rater reliability when measuring passive range
of movement in the lower limb in children with CP
(ICC >.80) and SEM of 3.5° [44, 45].
Inertial Motion sensors. Inertial motion sensors (see additional information
below) will be used to measure passive wrist extension
with fingers extended only.
Active range of movement: elbow extension,
wrist extension (with fingers extended), wrist
extension (with fingers flexed), supination
Standardised goniometric measurement
and use of inclinometer for measures of
supination.
See additional information above.
Inertial Motion sensors Inertial motion sensors (see additional information
below) will be used to measure active wrist extension
with fingers extended only.
Functional range of wrist extension during
standardised tasks.
Inertial Motion sensors. A wireless inertial motion sensor for children has been
designed and engineered for this trial to measure wrist
flexion/extension movement during functional activity.
The sensors use a combination of inertial sensor
technologies to provide an accurate estimate of
orientation referenced to a fixed frame [46]. Once
correctly positioned they wirelessly capture movement
with 3° of freedom in a virtual reality environment to
provide continuous kinematic data during unrestricted
functional movements. The validity and reliability of the
newly developed sensor has been assessed with 10
children with CP (aged 4–12 years) against 3DMA, the
‘gold standard’ method to quantify movement.
Preliminary data demonstrates the inertial motion
sensors have excellent static and dynamic accuracy
(+/-0.5 and +/-1.2° respectively).
Muscle stiffness (finger flexors, wrist flexors,
pronators and elbow flexors)
Modified Ashworth Scale [47] The six point Modified Ashworth Scale has moderate
intra-rater reliability when assessing the elbow (ICC 0.66)
and wrist flexors (ICC 0.57) in children with CP [48].
Muscle spasticity (finger flexors, wrist flexors,
pronators and elbow flexors)
Modified Tardieu Scale [47] The Modified Tardieu Scale has moderate to high
intra-rater reliability when assessing the elbow (ICC 0.65)
and wrist flexors (ICC 0.92) in children with CP [48].
Australian Spasticity Scale [33] The Australian Spasticity Assessment Scale has demonstrated
moderate to high inter-rater agreement (47–100 %) [33]
Grip strength Hand held dynamometer (CITEC) Dynamometery has been shown to have excellent levels
of inter-rater (ICC 0.95) and test-re-test reliability
(ICC 0.96) when measuring strength in the hand of
children with hemiplegic CP [49].
Hand deformity Neurological Hand Deformity
Classification Scale [50]
The Neurological Hand Deformity Classification has
evidence of reliability for children with spastic cerebral
palsy with high inter-rater agreement (Kappa 0.87) and
intra-rater agreement (Kappa 0.91) [15]
Thumb position House Thumb in Palm classification [51] This measure has been developed for children with CP
based on the predictors of surgical success and has been
found to be reliable: Kappa = 0.73 (rater agreement) and
0.74 (test-re-test agreement) [49, 52].
Hand pain Study specific questionnaire The study specific questionnaire was developed for this
study to document parent perception of domains unable
to be captured in existing measures. Questions will be
completed by the child where possible or by a parent/
carer proxy. Although proxy respondents are known to
underestimate pain, parent-reported pain will be required
for children who are more severely cognitively impaired
or unable to communicate their pain effectively.
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Table 2 Variables and outcome measures (Continued)
Activity domain of the ICF: baseline, 12, 24 & 36 months
Self-care skills Pediatric Evaluation of Disability
Inventory – Computer Adaptive Test [53]
This is a standardised assessment of how children with
impairments function in the context of their daily life.
The Pediatric Evaluation of Disability- Computer Aided Test
provides an accurate and precise assessment of abilities in
four functional domains (ICC 0.99). For this trial only data
from the Daily Activities domain will be collected.
Manual ability ABILHAND-Kids [54] This tool has been Rasch analysed and has demonstrated
validity and appropriate range and measurement precision
for clinical practice and research: reliability: R = 0.94;
reproducibility over time: R = 0.91 [54].
Speed and dexterity Box and Blocks Test [55] This test has a high level of intra-rater (ICC 0.99) and
test-retest reliability (ICC 0.85) [56].
Hand function Modified House Scale [57] This scale is reliable in children with CP: inter rater reliability
(ICC 0.94-0.96); intra rater reliability (ICC 0.93-0.96) [57].
Rasch analysis was performed on the original scale and the
items reduced: analysis suggests that the modified version
demonstrates good construct validity [58].
Ease of care-giving Study specific questionnaire Parent response to specific questions regarding the child’s
ability to use their hands in self-care tasks or, for children
with severe forms of cerebral palsy the ease with which
parents or carer’s can complete daily tasks of care for them.
Participation domain of ICF: Baseline & 3 years only
Participation Participation and Environment
Measure-Child & Youth [59]
Designed to measure frequency of participation,
involvement during participation and the impact of the
environment on participation in children aged 5 to17 years
[59]. This measure captures participation outcomes in
home, school and community contexts. Reliability of the
frequency scales (ICC range 0.58-0.84) and involvement
scales (ICC 0.69-0.76 is moderate to high [59].
Child Health related quality of life and
care-giving burden
Cerebral Palsy Quality of Life
Questionnaire – Child and Teen versions
[60, 61]
Due to the varying ages and abilities of the child-
participants, both parent- and self-report versions of the
Child or Teen CP Quality of Life will be used to measure
quality of life. Test-re-test reliability for the Child version
was high (ranged from ICC 0.76 to 0.89 across 7 scales)
[61], and moderate to high for the Teen version (ICC 0.57
to 0.88) [60]
Health economic measures: Baseline, 12, 24, 36 months
Cost Effectiveness Analysis (CEA) Study specific questionnaire Data on type and number of health professional
appointments attended by child in preceding 6-month
time period will be utilised for calculation of healthcare
cost as well as out of pocket costs to families. Net
incremental costs expressed as ICER to meaningful
clinical and physical outcomes (e.g. selected from body
function domains; activity domains; and the clinical quality
of life questionnaire).
Cost Utility Analysis (CUA) Child Health Utility -9 Dimensions [37] Net ICER to the quality of life improvement for children
and parents/carers expressed as QALY using an
economic MAUI. Where possible the Child Health Utility
will be completed along with the parent proxy version.
The Child Health Utility has 9 items, takes 2-3 min to
complete and covers worry, sadness, pain, tiredness, an
noyance, school work, sleep, daily routine and ability to
join in activities. The Child Health Utility-9D demonstrated
good validity and high levels of agreement with a similar
instrument (ICC: 0.742) [62]. The parent measure of quality
of life, the Assessment of Quality of Life 8 Dimensions has
high reliability (ICC 0.89) [36].
Assessment of Quality of Life 8
Dimensions [36]
Cost Consequences Analysis (CCA) CEA/CUA reported alongside a broader documentation
of child & family relevant outcomes
Note: ICC intraclass correlation coefficient, SEM standard error of measurement, 3DMA three dimensional motion analysis, ICER Incremental Costs Effectiveness
Ratio, MAUI multi-attribute health utility instruments, QALY quality adjusted life year, CEA Cost effectiveness analysis, CUA Cost utility analysis
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and implementation/policy issues (e.g. acceptability to
stakeholders, equity impacts, feasibility of implementation,
quality of the evidence base) using Assessment of Cost Ef-
fectiveness (ACE) methods. ACE has been used across a
series of commissioned and NHMRC-funded projects [38].
Costs will be calculated using pathway analysis to docu-
ment treatment activity, specify unit prices and estimate
costs and potential cost offsets across the study groups.
For usual multidisciplinary care, a number of pathways
will be constructed and analysed separately as well as a
weighted average comparator. Costs associated with the
WHO will be assessed by expenditure category (i.e. salar-
ies, overheads, consumables) with economic data collected
using a logbook; all other healthcare costs will be assessed
by incidence category (i.e. who bears the cost) using avail-
able information from sources such as the Medical Benefit
Schedule and Pharmaceutical Benefit Scheme. Sensitivity/
uncertainty analyses will be undertaken to investigate the
robustness of the ICERs to variations in key cost, pathway
and outcome parameters in the trial and across sites.
Data collection methods for child-participants who exit
prematurely
Children may exit prematurely from the study because
of voluntary withdrawal or termination of WHO inter-
vention due to harm (e.g. allergic reaction to materials).
Participant retention will be supported within the study
through provision of routine follow-up and regular feed-
back on child progress via the TherApp summary report
that can be generated by parents throughout the trial.
Where possible, all children will be followed to the study
end point (3 years) so that data are available for analyses.
Lack of adherence to the treatment plan will be recorded
using TherApp and will not constitute a reason for with-
drawal. Reasons for withdrawal from the intervention, or
the study, will be recorded to assist with management of
missing data and interpretation of results.
Monitoring of harm and adverse events
No harm or adverse events from orthoses are reported
in the literature but are occasionally noted in clinical
practice; these are temporary and non-sentinel. Harm
arising from the WHO could include the development
of pressure areas on the skin, pain, disturbed sleep or
behaviour, and skin allergies from specific splint mate-
rials while wearing the orthosis, and heat during orthosis
fabrication. Children in both groups are at risk of a reduc-
tion in joint range of movement as part of the natural
course of CP during growth and development. Adverse
events unrelated to the study may also occur and will be
adjudicated by the Data Monitoring Committee. Data re-
lated to harm and/or adverse events for all children will be
collected throughout the study by the therapist who man-
ufactures the WHO (routine follow up), retrospectively by
study research assistants (6 monthly) and via TherApp
alerts. If the TherApp registers an adverse event an au-
tomated email alert to the study research assistant will
enable appropriate follow up.
Data management
Data will be collected using a combination of paper-based
and web-based data forms supported by the secure Re-
search Electronic Data capture (REDCap) data man-
agement system [39] hosted at the Murdoch Childrens
Research Institute. REDCap supports quality control
measures including rule-based data entry to reduce data
entry errors. In addition, data cleaning will be undertaken.
Secure electronic data storage will be undertaken using
REDCap, and secure (locked) local storage of original
paper-based versions of data collected will occur in ac-
cordance with ethically approved procedures for each trial
site. Participants will be assigned identification codes on
enrolment to the study. These codes will be used during
data entry so that data are de-identified during analyses
and only aggregated data reported to protect the privacy
of participants.
Statistical methods
The primary analysis will be by intention to treat. Com-
parison between the intervention and the control groups
in the difference from baseline in the passive range of
wrist extension (primary outcome) will be presented as
the mean difference between the groups and its 95 %
confidence interval, obtained using linear regression ad-
justed for the stratification factors of site and range of
passive wrist extension at baseline. The regression model
will be fitted using generalised estimating equations (GEE)
to allow for the clustering of observations within children
for those with both limbs in the study. To explore the ef-
fect of the adherence to WHO wearing schedule (i.e. a
dose response relationship), a linear regression model will
be fitted with compliance to treatment as a predictor and
difference in the passive range of wrist extension from
baseline to 36 months as the outcome, applied to all study
participants. Again this model will be fitted using GEEs to
allow for the clustering of limbs within participants.
Evidence for an interaction between age and treatment,
and between severity (Neurological Hand Deformity
Classification) and treatment, will be explored by the
inclusion of interaction terms in the linear regression
models as well as GEE models. The analyses will be re-
peated, adjusting for potential confounders including occa-
sions of upper limb BoNT-A injections and frequency of
upper limb intervention. Analysis will also be undertaken
using the ‘per protocol’ population excluding children
who received surgical intervention or casting during the
study. All data available from children who are withdrawn
from the study prior to study completion will be used for
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analysis. Imputation of missing data will only be consid-
ered in the primary analysis if less than 10–20 % of the
primary outcome is missing and will be undertaken
throughout multiple imputation models.
Depending on whether data are continuous, categor-
ical or dichotomous, the appropriate generalized linear
model will be used to estimate the effect of treatment
across the study period on secondary outcomes, again
fitted using generalised estimating equations. All analyses
will be adjusted for the same stratification factors as for
the primary analysis and carried out on intention to treat
and per protocol populations.
Trial governance
A clinical trials agreement is in place between ACU and
each trial implementation site that indicates joint intellec-
tual property. A Steering Committee, which includes two
parent advisors and all chief investigators, will ensure the
study is completed according to the protocol, ethical stan-
dards and established timeframes. In addition, the Steering
committee will undertake management of the evaluation of
the trial and be responsible for establishing a dissemination
plan, including peer reviewed publications. Dissemination
activities, including attribution of authorship will be
undertaken in accordance with the Australian Code for
the Responsible Conduct of Research [40]. There are no
publication restrictions. The trial Management Committee,
based at ACU in Victoria will oversee and manage the day
to day operations of the study. State-based advisory groups
in Victoria, New South Wales and Western Australia will
undertake state-specific implementation. An independent
three-person Data Monitoring Committee will review,
based on the Damocles Charter, safety, efficacy, participant
retention and protocol compliance data and advise regard-
ing protocol variation [11].
Trial status
Ethical approval has been received from each participat-
ing site; study operating procedures and data collection
methods have been finalised; and staff recruited and trained
in reliable data collection. Recruitment commenced in
2015 and will be ongoing through 2016.
Discussion/conclusion
Hand dysfunction and deformity are prevalent in CP:
85 % of children have spasticity that impacts upper limb
structure and function, ≥62 % have wrist flexion deform-
ities, and early onset is common [41]. Strong positive
correlations exist between hand posture and function [9,
41]. Hand orthoses are time-consuming to make and are
challenging for families to implement and for children
to wear, but if they prevent deformity and improve hand
function, they are a vital treatment. This RCT should
provide high quality evidence to resolve the long debate
about the value of WHO and the specific impact of wrist
impairment on activity. In addition, three novel meas-
urement devices will be designed and/or engineered,
tested and validated in children within the conduct of
this trial: (i) TherApp; (ii) within-orthosis tactile sensors;
and (iii) inertial motion sensors. The further application
of these devices in a diverse range of clinical and research
contexts will constitute a significant intellectual and prac-
tical contribution to the health sciences. TherApp has po-
tential for application to support data collection in other
health intervention research trials and in clinical practice
to support the implementation of interventions and facili-
tate communication between clients and clinicians. Iner-
tial motion sensors have potential applicability to other
interventions focused on outcomes at the body structure
and function level of the ICF, such as BoNT-A, and the
tactile sensors may also provide data about orthosis fit as
well as wearing time, if placed within the orthosis at key
points of hand-orthosis contact.
The annual cost of CP in Australia is approximately
$1.5 billion (0.14 % of GDP) [42]. Lost wellbeing (as a
result of disability and premature death) can be valued
at a further $2.4 billion [42]. This research will provide
Level II (RCT) evidence [43] to inform clinicians, health
services, government funding bodies and parents and
carers of children with CP whether the provision of
orthoses to prevent upper limb impairment is worth the
effort and associated costs. This multicentre RCT along
with a companion RCT to be implemented with young
children under the age of 3 years will provide high qual-
ity evidence of the medium-term effect of rigid upper
limb orthoses in children with CP. The second trial aims
to determine whether provision of a rigid WHO can pre-
vent the occurrence of contracture and deformity in
children aged less than 3 years at time of recruitment.
By combining the use of rigid orthoses with usual multi-
disciplinary therapies, these two trials will investigate a
combined intervention more reflective of current best
practice than has been previously investigated. The
results will provide evidence as to whether the use of
rigid upper limb orthoses are needed, or if activity-
based therapy alone is sufficient to restore and pre-
vent musculoskeletal impairment in children and
adolescents with CP.
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